Videos

Studies With Amantadine-DR/ER for Treatment of Dyskinesia

The director of the Massachusetts General Hospital ALS Care Center talked about CNM-Au8 treatment across three populations, as well as the HEALEY ALS Platform Trial, at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease

The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

The Effects of Disease-Modifying Therapy on MS Cognitive Function

Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.

Stephen Krieger, MD

Accuracy of DCTclock to Detect Cognitive Impairment: Ali Jannati, MD, PhD

Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.

Ali Jannati, MD, PhD

Development of Neuropathology Targeted Treatments in Alzheimer Disease: Madhav R. Thambisetty, MD, PhD

The manager of Clinical Development-Research at Linus Health provided perspective on 2 analyses presented at the 2023 AAN Annual Meeting on the reliability of the DCTclock to detect cognitive impairment. [WATCH TIME: 4 minutes]

Madhav R. Thambisetty, MD, PhD

Preserving Cognitive Status in Pediatric Multiple Sclerosis: Kimberly O’Neill, MD

The senior investigator at the National Institute on Aging talked about targeting pathologies in neurodegenerative diseases at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]

Kimberly O'Neill, MD

Multiple Sclerosis Journey: Sharing Experiences

The pediatric neuroimmunology fellow at NYU Langone provided perspective on a study presented at AAN 2023 comparing cognitive trajectories of pediatric and adult multiple sclerosis. [WATCH TIME: 3 minutes]

June Halper, MSN, APC-C, MSCN, FAAN;Mary Ann Picone, MD;Gina Murdoch

Multiple Sclerosis Journey: Peer to Peer Support

The panel discusses the value of shared experiences among individuals living with multiple sclerosis.

June Halper, MSN, APC-C, MSCN, FAAN;Mary Ann Picone, MD;Gina Murdoch

Defining and Assessing Cognitive Function in Multiple Sclerosis

Craig Mainor and Gina Murdoch share peer-to-peer support resources for individuals living with multiple sclerosis.

Stephen Krieger, MD

Targeting Neuroinflammation in Huntington Disease: Rajeev Kumar, MD

Stephen Krieger, MD, discusses how cognition is defined in multiple sclerosis and the tools to evaluate patients' cognitive performance.

Rajeev Kumar, MD

April 23rd 2023

Associations Between Organ Health and Brain Function, Preserving Brain Health: Costantino Iadecola, MD

The medical director of the Rocky Mountain Movement Disorders Center talked about the motivations of the phase 2 study on ANX005 for Huntington disease at the 2023 AAN Annual Meeting. [WATCH TIME: 3 minutes]

Costantino Iadecola, MD

April 23rd 2023

Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine spoke about preserving brain function through medical, sociopolitical, and educational efforts as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

Kathryn A. Davis, MD, FAES

April 22nd 2023

Targeting Blood Vessels to Improve Treatment for Alzheimer Disease: Costantino Iadecola, MD

The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Costantino Iadecola, MD

April 22nd 2023

DEA Rules Fenfluramine No Longer Controlled Substance, Positive FDA ADComm Meeting of Brexpiprazole, Antiamyloid Drugs Accelerate Brain Atrophy

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about the importance of vascular health in preventing cognitive impairment as part of his presentation at the 2023 AAN annual meeting. [WATCH TIME: 6 minutes]

NeurologyLive® Staff

April 22nd 2023

Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal Mickle

Neurology News Network for the week ending April 22, 2023. [WATCH TIME: 4 minutes]

Christal Mickle

April 21st 2023

Advances in Neurology, Contributions to Brain Health: Costantino Iadecola, MD

The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]

Costantino Iadecola, MD

April 20th 2023

Burden and Risk Factor of Narcolepsy

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Narcolepsy Overview

Significance of New MOGAD Diagnosis Criteria, Inclusion of MOG-IgG: Anastasia Vishnevetsky, MD

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

Anastasia Vishnevetsky, MD

Determining Treatment Efficacy in the Treatment of Myasthenia Gravis

An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]

A. Gordon Smith, MD, FAAN

Evolving Approaches to Treatment Selection in the Management of Myasthenia Gravis

A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.

A. Gordon Smith, MD, FAAN

Use of FDA Approved Disease-Modifying Therapies vs Other Treatments in NMOSD

A. Gordon Smith, MD, FAAN, talks about how new agents and emerging data are enabling clinicians to personalize care for patients with myasthenia gravis.

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Effects of Polymorphism in the Use of Anti-CD19 and Anti-CD20 B-cell Therapy in NMOSD

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Brian G. Weinshenker, MD;Flavia Nelson, MD;Robert Shin, MD, FAAN;Aaron Miller, MD, FAAN

Analyzing Specific Pathways in Cells to Prevent Relapse in NMOSD: Shuhei Nishiyama, MD, PhD

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

Shuhei Nishiyama, MD, PhD

Treatment of Dyskinesia in Patients with Parkinson’s Disease

The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease

Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.

Daniel E. Kremens, MD, JD;Rajesh Pahwa, MD;Robert A. Hauser, MD, MBA;William Ondo, MD;Fernando L. Pagán, MD

Rehab Process and Need for Improved Guidelines of Basilar Artery Occlusions: Russell Cerejo, MD

The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.

Russell Cerejo, MD

Recognizing the Symptoms and Diagnostic Workup in NMDA Receptor Encephalitis: Gregory Day, MD, MSc, MSCI, FAAN

The vascular neurologist at Allegheny Health Network provided insight on the need to create consensus guidelines that further explain the treatment, management, and rehab of basilar artery occlusions. [WATCH TIME: 3 minutes]

Gregory Day, MD, MSc, MSCI, FAAN